Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 2.96.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 35 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:42:33.611Z. Historical observations retain their original dates. Historical series through 2020-03-02.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
22.45
EARNINGS PER SHARE (EPS) AVG 3Y
9.70
EARNINGS PER SHARE (EPS) AVG 5Y
5.59
EARNINGS PER SHARE (EPS) AVG 10Y
2.50
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kyntra Bio, Inc.
Market Cap
$24.59M
Earnings Per Share (EPS)
N/A
TTM Avg
22.45
3Y Avg
9.70
5Y Avg
5.59
Market Cap
$24.59M
Earnings Per Share (EPS)
-4.34
TTM Avg
-3.52
3Y Avg
-3.45
5Y Avg
-7.67
Market Cap
$24.30M
Earnings Per Share (EPS)
-0.29
TTM Avg
-0.41
3Y Avg
-1.95
5Y Avg
-2.99
Market Cap
$22.64M
Earnings Per Share (EPS)
-32.78
TTM Avg
-24.95
3Y Avg
-26.53
5Y Avg
-21.18
Market Cap
$27.17M
Earnings Per Share (EPS)
-0.50
TTM Avg
-0.76
3Y Avg
-1.17
5Y Avg
-2.27
Market Cap
$21.90M
Earnings Per Share (EPS)
-1.66
TTM Avg
-1.66
3Y Avg
-2.82
5Y Avg
-25.82
Market Cap
$27.31M
Earnings Per Share (EPS)
-2.41
TTM Avg
-9.11
3Y Avg
-20.57
5Y Avg
-19.82
Market Cap
$28.42M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.83
3Y Avg
-1.05
5Y Avg
-1.29
Market Cap
$20.21M
Earnings Per Share (EPS)
-10.06
TTM Avg
-13.83
3Y Avg
-22.37
5Y Avg
-34.56
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | $24.59M | N/A | 22.45 | 9.70 | 5.59 |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.59M | -4.34 | -3.52 | -3.45 | -7.67 |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.30M | -0.29 | -0.41 | -1.95 | -2.99 |
| LeonaBio, Inc. (LONA)vs › | $22.64M | -32.78 | -24.95 | -26.53 | -21.18 |
| InspireMD, Inc. (NSPR)vs › | $27.17M | -0.50 | -0.76 | -1.17 | -2.27 |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | -1.66 | -1.66 | -2.82 | -25.82 |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.31M | -2.41 | -9.11 | -20.57 | -19.82 |
| aTyr Pharma, Inc. (ATYR)vs › | $28.42M | -0.62 | -0.83 | -1.05 | -1.29 |
| Modular Medical, Inc. (MODD)vs › | $20.21M | -10.06 | -13.83 | -22.37 | -34.56 |
| GridAI Technologies Corp. (GRDX)vs › | $29.17M | -4.31 | -4.75 | -350.99 | -43000.60 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
$-9.65
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 45.37 |
| 2024-12-31 | -0.48 |
| 2023-12-31 | -2.92 |
| 2022-12-31 | -3.15 |
| 2021-12-31 | -3.15 |
| 2020-12-31 | -2.11 |
| 2019-12-31 | -0.89 |
| 2018-12-31 | -1.03 |
| 2017-12-31 | -1.73 |
| 2016-12-31 | -0.98 |
| 2015-12-31 | -1.42 |
| 2014-12-31 | -1.04 |
| 2013-12-31 | -0.32 |
| 2012-12-31 | -2.47 |
